The latest price of capmatinib in the domestic market

Capmatinib , as a targeted treatment drug for MET mutation non-small cell lung cancer (NSCLC) , has gradually entered the Chinese market in recent years and has been included in the national medical insurance directory. This is a major progress in the accessibility of drugs to domestic patients. According to current market data, the original drug capmatinib has been launched in China and has been officially approved. The trade name is Tabrecta. The specifications are usually 150 mg 60 tablets or 200 mg 60 tablets. Each box sells for about 30,000 yuan. Covered by the medical insurance reimbursement policy, patients' out-of-pocket expenses are significantly reduced, which greatly eases the financial burden of medication, making it a realistic and feasible option in the field of precision treatment.

In overseas markets, especially in Europe, the selling price of capmatinib’s original drug is significantly higher than the domestic price, with some specifications even reaching more than 50,000 yuan per box. This price difference is mainly affected by various factors such as regional pricing policies, the breadth of medical insurance coverage, and exchange rate changes. It is also related to the global market strategy of the original drug company. Although the price of drugs is high, in developed countries such as Europe, most patients can obtain part or all of the cost reimbursement through commercial insurance or the national medical system, and the economic threshold for clinical use of drugs is relatively low.

It is worth noting that as the patent protection period of capmatinib advances and market demand grows, some overseas generic drugs have begun to appear, especially in countries with relatively developed generic drug industries such as Laos and India. For example, a pharmaceutical company in Laos has launched a 200mg*56-tablet generic version of Capmatinib, which is priced at just over RMB 2,000. Although it has not yet received formal marketing approval from the China State Food and Drug Administration, it is still sold in some countries and regions around the world. The chemical composition of these generic drugs is basically the same as that of the original drugs, but whether they fully meet the standards of the original drugs in terms of quality control, stability and bioequivalence still requires rigorous evaluation.

Reference materials:https://www.drugs.com/mtm/capmatinib.html